Syntaxin as a biopharmaceutical company focusses on the bacterial-based protein therapeutics for the treatment of chronic diseases.
Business Model:
Revenue: $4.8M
Employees: 51-200
Syntaxin Ltd. was acquired by
Ipsen.
The acquisition happend on 2013-07-15.
Details of the transaction were not public
Address: Units 4-10 The Quadrant Barton Lane
City: Oxon
State: england
Zip: OX14 3YS
Country: GB
Syntaxin as a biopharmaceutical company focusses on the bacterial-based protein therapeutics for the treatment of chronic diseases.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 11/2010 | Series C | 7 | $29M |
Abingworth Ipsen Johnson &a; Johnson Development Corporation LSP BioVentures Lundbeckfonden Ventures Seventure Partners SR One Abingworth Ipsen Johnson &a; Johnson Development Corporation LSP BioVentures Lundbeckfonden Ventures Seventure Partners SR One |
10/2007 | Series B | 5 | $32M |
Abingworth Johnson &a; Johnson Development Corporation Life Sciences Partners Quest for Growth SR One Abingworth Johnson &a; Johnson Development Corporation Life Sciences Partners Quest for Growth SR One |
11/2005 | Series A | 1 | $10.4M |
Abingworth Abingworth |
9/2007 | Series B | $32M |
SrOne Johnson & Johnson Abingworth |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|